Optimizations of SiRNA Design for the Activation of Gene Transcription by Targeting the TATA-Box Motif

Small interfering RNAs (siRNAs) are widely used to repress gene expression by targeting mRNAs. Some reports reveal that siRNAs can also activate or inhibit gene expression through targeting the gene promoters. Our group has found that microRNAs (miRNAs) could activate gene transcription via interaction with the TATA-box motif in gene promoters. To investigate whether siRNA targeting the same region could upregulate the promoter activity, we test the activating efficiency of siRNAs targeting the TATA-box motif of 16 genes and perform a systematic analysis to identify the common features of the functional siRNAs for effective activation of gene promoters. Further, we try various modifications to improve the activating efficiency of siRNAs and find that it is quite useful to design the promoter-targeting activating siRNA by following several rules such as (a) complementary to the TATA-box-centered region; (b) UA usage at the first two bases of the antisense strand; (c) twenty-three nucleotides (nts) in length; (d) 2′-O-Methyl (2′-OMe) modification at the 3′ terminus of the antisense strand; (e) avoiding mismatches at the 3′ end of the antisense strand. The optimized activating siRNAs potently enhance the expression of interleukin-2 (IL-2) gene in human and mouse primary CD4+ T cells with a long-time effect. Taken together, our study provides a guideline for rational design the promoter-targeting siRNA to sequence-specifically enhance gene expression.

[1]  Emmanuel C. Alozie,et al.  Promises and Challenges , 2015 .

[2]  G. Geng,et al.  A novel HIV-1-encoded microRNA enhances its viral replication by targeting the TATA box region , 2014, Retrovirology.

[3]  C. Rice,et al.  MX2 is an interferon-induced inhibitor of HIV-1 infection , 2013, Nature.

[4]  J. Doudna,et al.  Molecular mechanisms of RNA interference. , 2013, Annual review of biophysics.

[5]  J. Engels Gene silencing by chemically modified siRNAs. , 2013, New biotechnology.

[6]  Giovanna Ambrosini,et al.  EPD and EPDnew, high-quality promoter resources in the next-generation sequencing era , 2012, Nucleic Acids Res..

[7]  Jing Liu,et al.  Single-Stranded RNAs Use RNAi to Potently and Allele-Selectively Inhibit Mutant Huntingtin Expression , 2012, Cell.

[8]  Stanley T. Crooke,et al.  Single-Stranded siRNAs Activate RNAi in Animals , 2012, Cell.

[9]  R. Place,et al.  Upregulation of Cyclin B1 by miRNA and its implications in cancer , 2011, Nucleic acids research.

[10]  D. Cooper,et al.  Transcriptional gene silencing of HIV-1 through promoter targeted RNA is highly specific , 2011, RNA biology.

[11]  D. Perkins,et al.  Nuclear and cytoplasmic localization of neural stem cell microRNAs. , 2011, RNA.

[12]  Scott T. Younger,et al.  Transcriptional gene silencing in mammalian cells by miRNA mimics that target gene promoters , 2011, Nucleic acids research.

[13]  Yongjun Chu,et al.  Involvement of argonaute proteins in gene silencing and activation by RNAs complementary to a non-coding transcript at the progesterone receptor promoter , 2010, Nucleic acids research.

[14]  Hui Zhou,et al.  Deep Sequencing of Human Nuclear and Cytoplasmic Small RNAs Reveals an Unexpectedly Complex Subcellular Distribution of miRNAs and tRNA 3′ Trailers , 2010, PloS one.

[15]  G. Stoecklin,et al.  On track with P-bodies. , 2010, Biochemical Society transactions.

[16]  A. Goodchild,et al.  Intended transcriptional silencing with siRNA results in gene repression through sequence-specific off-targeting. , 2010, RNA.

[17]  J. Doudna,et al.  Structural insights into the human GW182-PABC interaction in microRNA-mediated deadenylation , 2010, Nature Structural &Molecular Biology.

[18]  F. Holstege,et al.  Distinct promoter dynamics of the basal transcription factor TBP across the yeast genome , 2009, Nature Structural &Molecular Biology.

[19]  D. Cooper,et al.  Retroviral delivery of promoter-targeted shRNA induces long-term silencing of HIV-1 transcription. , 2009, Microbes and infection.

[20]  J. Kjems,et al.  A large-scale chemical modification screen identifies design rules to generate siRNAs with high activity, high stability and low toxicity , 2009, Nucleic acids research.

[21]  V. Patzel,et al.  siRNA stabilization prolongs gene knockdown in primary T lymphocytes , 2008, European journal of immunology.

[22]  D. Corey,et al.  Antisense transcripts are targets for activating small RNAs , 2008, Nature Structural &Molecular Biology.

[23]  J. T. Kadonaga,et al.  The RNA polymerase II core promoter - the gateway to transcription. , 2008, Current opinion in cell biology.

[24]  A. F. Bochner,et al.  An Argonaute Transports siRNAs from the Cytoplasm to the Nucleus , 2008, Science.

[25]  K. Ui-Tei,et al.  Functional dissection of siRNA sequence by systematic DNA substitution: modified siRNA with a DNA seed arm is a powerful tool for mammalian gene silencing with significantly reduced off-target effect , 2008, Nucleic acids research.

[26]  R. Place,et al.  MicroRNA-373 induces expression of genes with complementary promoter sequences , 2008, Proceedings of the National Academy of Sciences.

[27]  David R Corey,et al.  Chemical modification: the key to clinical application of RNA interference? , 2007, The Journal of clinical investigation.

[28]  Boris Lenhard,et al.  Mammalian RNA polymerase II core promoters: insights from genome-wide studies , 2007, Nature Reviews Genetics.

[29]  D. Corey,et al.  Activating gene expression in mammalian cells with promoter-targeted duplex RNAs. , 2007, Nature chemical biology.

[30]  E. Wentzel,et al.  A Hexanucleotide Element Directs MicroRNA Nuclear Import , 2007, Science.

[31]  Anthony D. Keefe,et al.  Building oligonucleotide therapeutics using non-natural chemistries. , 2006, Current opinion in chemical biology.

[32]  R. Place,et al.  Small dsRNAs induce transcriptional activation in human cells , 2006, Proceedings of the National Academy of Sciences.

[33]  D. Corey,et al.  Involvement of AGO1 and AGO2 in mammalian transcriptional silencing , 2006, Nature Structural &Molecular Biology.

[34]  L. Lim,et al.  Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing. , 2006, RNA.

[35]  K. Alexander,et al.  High potency silencing by single-stranded boranophosphate siRNA , 2006, Nucleic acids research.

[36]  Aleksey Y. Ogurtsov,et al.  Computational models with thermodynamic and composition features improve siRNA design , 2006, BMC Bioinformatics.

[37]  Chinmay Y. Majmudar,et al.  Chemical approaches to transcriptional regulation. , 2005, Current opinion in chemical biology.

[38]  A. Pasquinelli,et al.  Regulation by let-7 and lin-4 miRNAs Results in Target mRNA Degradation , 2005, Cell.

[39]  D. Corey,et al.  Inhibiting gene expression at transcription start sites in chromosomal DNA with antigene RNAs , 2005, Nature chemical biology.

[40]  Bernd Jagla,et al.  Sequence characteristics of functional siRNAs. , 2005, RNA.

[41]  R. Griffey,et al.  Positional effect of chemical modifications on short interference RNA activity in mammalian cells. , 2005, Journal of medicinal chemistry.

[42]  Sangdun Choi,et al.  Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy , 2005, Nature Biotechnology.

[43]  R. Griffey,et al.  Fully 2'-modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering RNA. , 2005, Journal of medicinal chemistry.

[44]  P. Dervan,et al.  Small molecule transcription factor mimic. , 2004, Journal of the American Chemical Society.

[45]  Matthias John,et al.  Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs , 2004, Nature.

[46]  Marion Jurk,et al.  Modulation of CpG oligodeoxynucleotide-mediated immune stimulation by locked nucleic acid (LNA). , 2004, Oligonucleotides.

[47]  P. Zamore,et al.  Kinetic analysis of the RNAi enzyme complex , 2004, Nature Structural &Molecular Biology.

[48]  Anton P. McCaffrey,et al.  In vivo activity of nuclease-resistant siRNAs. , 2004, RNA.

[49]  A. Reynolds,et al.  Rational siRNA design for RNA interference , 2004, Nature Biotechnology.

[50]  K. Ui-Tei,et al.  Guidelines for the selection of highly effective siRNA sequences for mammalian and chick RNA interference. , 2004, Nucleic acids research.

[51]  C. Burge,et al.  Prediction of Mammalian MicroRNA Targets , 2003, Cell.

[52]  T. Du,et al.  Asymmetry in the Assembly of the RNAi Enzyme Complex , 2003, Cell.

[53]  S. Jayasena,et al.  Functional siRNAs and miRNAs Exhibit Strand Bias , 2003, Cell.

[54]  Bo Liu,et al.  Transcription activation by a PNA-peptide chimera in a mammalian cell extract. , 2003, Chemistry & biology.

[55]  T. Rana,et al.  siRNA function in RNAi: a chemical modification analysis. , 2003, RNA.

[56]  H. Herweijer,et al.  Progress and prospects: naked DNA gene transfer and therapy , 2003, Gene Therapy.

[57]  M. Amarzguioui,et al.  Tolerance for mutations and chemical modifications in a siRNA. , 2003, Nucleic acids research.

[58]  A. Ansari,et al.  Modular design of artificial transcription factors. , 2002, Current opinion in chemical biology.

[59]  M. Ptashne,et al.  Design of artificial transcriptional activators with rigid poly-L-proline linkers. , 2002, Journal of the American Chemical Society.

[60]  Phillip D Zamore,et al.  Evidence that siRNAs function as guides, not primers, in the Drosophila and human RNAi pathways. , 2002, Molecular cell.

[61]  F. Bushman,et al.  Inhibition of Retroviral Pathogenesis by RNA Interference , 2002, Current Biology.

[62]  R. Andino,et al.  Short interfering RNA confers intracellular antiviral immunity in human cells , 2002, Nature.

[63]  J. Lieberman,et al.  siRNA-directed inhibition of HIV-1 infection , 2002, Nature Medicine.

[64]  Ali Ehsani,et al.  Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells , 2002, Nature Biotechnology.

[65]  T. Tuschl,et al.  Analysis of gene function in somatic mammalian cells using small interfering RNAs. , 2002, Methods.

[66]  T. Tuschl,et al.  Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate , 2001, The EMBO journal.

[67]  P. Zamore,et al.  ATP Requirements and Small Interfering RNA Structure in the RNA Interference Pathway , 2001, Cell.

[68]  M. Ptashne,et al.  Towards a minimal motif for artificial transcriptional activators. , 2001, Chemistry & biology.

[69]  T. Tuschl,et al.  RNA interference is mediated by 21- and 22-nucleotide RNAs. , 2001, Genes & development.

[70]  S. Hammond,et al.  An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells , 2000, Nature.

[71]  M. Manoharan 2'-carbohydrate modifications in antisense oligonucleotide therapy: importance of conformation, configuration and conjugation. , 1999, Biochimica et biophysica acta.

[72]  P. D. Cook,et al.  Making drugs out of oligonucleotides: a brief review and perspective. , 1999, Nucleosides & nucleotides.

[73]  R. Davis,et al.  Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways , 1996, Journal of Molecular Medicine.

[74]  N. Sugimoto,et al.  Thermodynamic parameters to predict stability of RNA/DNA hybrid duplexes. , 1995, Biochemistry.

[75]  P. D. Cook,et al.  Characterization of fully 2'-modified oligoribonucleotide hetero- and homoduplex hybridization and nuclease sensitivity. , 1995, Nucleic acids research.

[76]  P. D. Cook,et al.  Evaluation of 2'-modified oligonucleotides containing 2'-deoxy gaps as antisense inhibitors of gene expression. , 1993, The Journal of biological chemistry.

[77]  A. Baldwin,et al.  Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of I kappa B alpha: a mechanism for NF-kappa B activation , 1993, Molecular and cellular biology.

[78]  A. Murakami,et al.  Hybridization arrest of globin synthesis in rabbit reticulocyte lysates and cells by oligodeoxyribonucleoside methylphosphonates. , 1985, Biochemistry.

[79]  P. Miller,et al.  Oligothymidylate analogues having stereoregular, alternating methylphosphonate/phosphodiester backbones as primers for DNA polymerase. , 1982, Biochemistry.

[80]  Will French Function I , 1937 .

[81]  K. Ui-Tei,et al.  Human TNRC6A is an Argonaute-navigator protein for microRNA-mediated gene silencing in the nucleus. , 2013, RNA.

[82]  T. Rana,et al.  Illuminating the silence: understanding the structure and function of small RNAs , 2007, Nature Reviews Molecular Cell Biology.

[83]  B. Reinhart,et al.  A biochemical framework for RNA silencing in plants. , 2003, Genes & development.

[84]  M. Stevenson,et al.  Modulation of HIV-1 replication by RNA interference , 2002, Nature.

[85]  Brett,et al.  Evaluation of 2”Modified Oligonucleotides Containing 2’-Deoxy Gaps as Antisense Inhibitors of Gene Expression* , 2001 .

[86]  Leaf Huang,et al.  Nonviral gene therapy: promises and challenges , 2000, Gene Therapy.

[87]  H. Pahl,et al.  Activators and target genes of Rel/NF-kappaB transcription factors. , 1999, Oncogene.

[88]  T. Mukhopadhyay,et al.  Antisense therapy for cancer. , 1995, The cancer journal from Scientific American.